![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
01 Polfa Tarchomin (2)
02 Actavis Inc (3)
03 Aurobindo Pharma Limited (1)
04 Austell Laboratories (2)
05 GALDERMA LABS LP (2)
06 Galderma (7)
07 Hiral Labs (1)
08 NRIM Limited, (1)
09 Neogen N.V. (2)
10 Titan Laboratories (2)
01 CAP (4)
02 CAPSULE (2)
03 Capsule (4)
04 Capsule, hard (4)
05 HARD CAPSULES (4)
06 Hard Capsule (2)
07 Limeciclina 408Mg 28 Combined Oral Use (2)
08 Blank (1)
01 Dossier Availability: Q3 2025 (2)
02 Generic (4)
03 Originator (2)
04 Blank (15)
01 Leciclina (1)
02 Lymac 300mg (1)
03 Lymecyclin Actavis (2)
04 Lymecycline 300 mg Unicorn (1)
05 Lymecycline Actavis (1)
06 Tetralysal (8)
07 lymecycline NRIM (1)
08 Blank (8)
01 Canada (2)
02 India (3)
03 Italy (3)
04 Norway (4)
05 Poland (2)
06 South Africa (4)
07 Sweden (4)
08 Switzerland (1)